Contrary to the action of mACh antagonists, the administration of physostigmine, an AChE inhibitor, produced a motion sickness-like syndrome, including nausea, vomiting, discomfort, anxiety, and increases in ACTH, beta-endorphin, cortical and prolactin plasma levels [69]. The gene discussed is POMC; the disease is motion sickness.